ASND
Ascendis Pharma A/S
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-13/100
Last price
228.01
▼ 0.02 (0.01%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
228.03
Prev close
228.03
Day high
230.91
Day low
222.72
Volume
1.09M
Market cap
$14.87B
P/E (TTM)
17.47
52W range
186.05 – 282.15
Day trading desk
Gap from prior close
+0.00%
Prior close 228.03
VWAP
227.51
+0.22% from price
Relative volume
1.32×
Normal
Session range
3.68%
222.71 – 230.91
Position in range
65%
Mid range
ATR (14D)
7.32
3.21% of price
Prior day high
230.73
PDH
Prior day low
226.84
PDL
Bid / ask spread
—
Quote not published
Session volume
855.73K
Avg 650.62K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-0.89%
-2.8%
1M
-16.45%
-17.6%
3M
-18.45%
-23.0%
6M
+2.53%
-15.7%
YTD
+6.01%
-8.2%
1Y
+10.78%
-5.6%
3Y
+141.40%
+59.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ASND open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-16.45K
Net selling
Buy transactions
6
6.25K shares
Sell transactions
3
22.70K shares
Net transactions
+9
Buys less sells
Sell : buy shares
3.6 : 1
Mixed
Insider-held shares
509.62K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | BODENHOFF MADS Officer |
SELL | 3.00K | $810.57K | Direct |
| Sep 8, 26 | BODENHOFF MADS Officer |
CONVERSION | 3.00K | $330.00K | Direct |
| Sep 2, 26 | HOLTUG LARS Director |
SELL | 236 | $62.34K | Direct |
| Aug 14, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 2.00K | $492.65K | Direct |
| Jun 2, 26 | SMITH SCOTT THOMAS Chief Financial Officer |
BUY | 100 | $21.90K | Direct |
| May 29, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 500 | $111.56K | Direct |
| May 29, 26 | SMITH SCOTT THOMAS Chief Financial Officer |
BUY | 250 | $55.83K | Direct |
| May 26, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 400 | $95.12K | Direct |
| May 11, 26 | JENSEN FLEMMING STEEN Officer |
SELL | 19.46K | $4.64M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BIENAIME JEAN-JACQUES |
Director | 2.90K | Purchase |
BODENHOFF MADS |
Officer | 0 | Sale |
HOLTUG LARS |
Director | 4.00K | Sale |
JENSEN FLEMMING STEEN |
Officer | 0 | Sale |
SMITH SCOTT THOMAS |
Chief Financial Officer | 4.37K | Purchase |
Fundamentals
Market cap$14.87B
Enterprise value$14.48B
Revenue (TTM)$1.05B
Gross profit$955.89M
EBITDA$263.45M
Net income$741.76M
EPS (TTM)$12.94
Free cash flow$12.77M
Total cash$812.26M
Total debt$450.07M
Book value / share$24.62
Shares outstanding65.80M
Float65.64M
Short % of float7.13%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E17.47
Forward P/E20.96
PEG ratio—
Price / sales—
Price / book9.18
EV / revenue13.83
EV / EBITDA54.98
Gross margin91.30%
Operating margin64.98%
Profit margin70.84%
Return on equity118.78%
Return on assets9.58%
Debt / equity31.33
Current ratio2.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $720.13M | $363.64M | $266.72M | $51.17M | +98.0% |
| Operating revenue | $720.13M | $363.64M | $266.72M | $51.17M | +98.0% |
| Cost of revenue | $94.92M | $44.26M | $44.40M | $12.14M | +114.5% |
| Gross profit | $625.22M | $319.38M | $222.32M | $39.04M | +95.8% |
| Research & development | $303.62M | $307.00M | $413.45M | $379.62M | -1.1% |
| Selling, general & admin | $448.04M | $284.08M | $264.41M | $215.85M | +57.7% |
| Total operating expense | $761.49M | $598.15M | $677.86M | $600.85M | +27.3% |
| Operating income | -$136.27M | -$278.76M | -$455.54M | -$561.81M | +51.1% |
| Net interest income | -$44.88M | -$39.90M | -$12.55M | -$23.26M | -12.5% |
| Pre-tax income | -$212.65M | -$373.24M | -$474.14M | -$577.82M | +43.0% |
| Tax provision | $15.38M | $4.84M | $7.30M | $5.38M | +217.6% |
| Net income | -$228.03M | -$378.08M | -$481.45M | -$583.19M | +39.7% |
| Net income to common | -$228.03M | -$378.08M | -$481.45M | -$583.19M | +39.7% |
| Basic EPS | -3.76 | -6.53 | -8.55 | -10.40 | +42.4% |
| Diluted EPS | -3.76 | -6.53 | -8.55 | -10.40 | +42.4% |
| EBIT | -$132.00M | -$307.74M | -$430.08M | -$547.13M | +57.1% |
| EBITDA | -$114.31M | -$290.02M | -$411.17M | -$529.18M | +60.6% |
| Basic shares | 60.61M | 57.89M | 57.89M | 56.07M | +4.7% |
| Diluted shares | 60.61M | 57.89M | 57.89M | 56.07M | +4.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $616.04M | $559.54M | $392.16M | $444.77M | +10.1% |
| Cash & short-term investments | $616.04M | $559.54M | $399.44M | $735.46M | +10.1% |
| Accounts receivable | $141.33M | $166.28M | $35.87M | $11.91M | -15.0% |
| Inventory | $301.53M | $295.61M | $208.93M | $130.67M | +2.0% |
| Total current assets | $1.11B | $1.06B | $702.72M | $923.47M | +4.5% |
| Property, plant & equipment | $146.48M | $98.71M | $110.63M | $129.09M | +48.4% |
| Goodwill & intangibles | $3.71M | $4.03M | $4.42M | $4.83M | -7.9% |
| Total assets | $1.30B | $1.18B | $825.59M | $1.09B | +10.4% |
| Total current liabilities | $1.07B | $907.86M | $736.51M | $716.78M | +17.8% |
| Current debt | $486.53M | $491.54M | $421.27M | $412.98M | -1.0% |
| Long-term debt | $385.25M | $365.08M | $223.00M | $95.40M | +5.5% |
| Total debt | $871.79M | $856.62M | $644.26M | $508.38M | +1.8% |
| Total liabilities | $1.47B | $1.29B | $971.28M | $826.39M | +14.0% |
| Shareholder equity | -$162.82M | -$105.71M | -$145.70M | $263.35M | -54.0% |
| Working capital | $39.59M | $153.00M | -$33.79M | $206.69M | -74.1% |
| Net tangible assets | -$166.53M | -$109.73M | -$150.12M | $258.52M | -51.8% |
| Shares issued | 61.98M | 60.69M | 57.71M | 58.27M | +2.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$228.03M | -$378.08M | -$481.45M | -$583.19M | +39.7% |
| Depreciation & amortisation | $17.70M | $17.71M | $18.91M | $17.96M | -0.1% |
| Stock-based compensation | $116.17M | $95.51M | $66.66M | $64.18M | +21.6% |
| Change in working capital | $70.96M | -$107.16M | -$99.79M | -$12.47M | +166.2% |
| Operating cash flow | $53.90M | -$306.20M | -$467.36M | -$495.70M | +117.6% |
| Capital expenditure | -$8.48M | -$1.43M | -$2.44M | -$14.49M | -494.6% |
| Investing cash flow | -$8.48M | $6.88M | $286.47M | $61.73M | -223.4% |
| Share buybacks | -$17.40M | $0 | $0 | -$105.31M | — |
| Financing cash flow | $36.33M | $443.93M | $134.29M | $396.77M | -91.8% |
| Free cash flow | $45.41M | -$307.62M | -$469.80M | -$510.19M | +114.8% |
| End cash position | $616.04M | $559.54M | $392.16M | $444.77M | +10.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $339.29M | $246.60M | $247.50M | $213.63M | $158.04M | +37.6% |
| Operating revenue | $339.29M | $246.60M | $247.50M | $213.63M | $158.04M | +37.6% |
| Cost of revenue | $27.66M | $17.52M | $23.60M | $22.35M | $31.45M | +57.9% |
| Gross profit | $311.63M | $229.09M | $223.90M | $191.28M | $126.60M | +36.0% |
| Research & development | $75.89M | $59.04M | $78.15M | $66.88M | $71.99M | +28.5% |
| Selling, general & admin | $171.68M | $145.23M | $135.00M | $111.69M | $105.71M | +18.2% |
| Total operating expense | $91.16M | $204.27M | $217.46M | $180.28M | $179.55M | -55.4% |
| Operating income | $220.47M | $24.81M | $6.44M | $11.00M | -$52.95M | +788.5% |
| Net interest income | -$1.03M | -$62.74M | $4.30M | -$16.39M | -$26.72M | +98.4% |
| Pre-tax income | $230.09M | -$48.18M | -$26.70M | -$57.37M | -$35.01M | +577.6% |
| Tax provision | $23.12M | -$677.52M | $6.86M | $3.62M | $3.85M | +103.4% |
| Net income | $206.97M | $629.34M | -$33.56M | -$60.99M | -$38.85M | -67.1% |
| Net income to common | $206.97M | $629.34M | -$33.56M | -$60.99M | -$38.85M | -67.1% |
| Basic EPS | 3.22 | 10.20 | -0.55 | -1.00 | -0.64 | -68.4% |
| Diluted EPS | 2.83 | 9.75 | -0.55 | -1.00 | -0.82 | -71.0% |
| EBIT | $244.27M | $19.08M | -$6.17M | -$37.65M | -$15.49M | +1,180.4% |
| EBITDA | $248.84M | $23.30M | -$1.34M | -$33.63M | -$11.19M | +968.1% |
| Basic shares | 64.34M | 61.68M | 61.02M | 60.76M | 60.45M | +4.3% |
| Diluted shares | 68.32M | 64.52M | 61.02M | 60.76M | 63.91M | +5.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $812.26M | $572.82M | $616.04M | $539.09M | $494.05M | — | +41.8% |
| Cash & short-term investments | $812.26M | $572.82M | $616.04M | $539.09M | $494.05M | — | +41.8% |
| Accounts receivable | $206.50M | $178.68M | $141.33M | $134.73M | $110.45M | — | +15.6% |
| Inventory | $310.58M | $314.34M | $301.53M | $302.02M | $303.38M | — | -1.2% |
| Total current assets | $1.39B | $1.12B | $1.11B | $1.02B | $952.96M | — | +23.9% |
| Property, plant & equipment | $135.69M | $135.92M | $146.48M | $101.76M | $93.54M | — | -0.2% |
| Goodwill & intangibles | $3.68M | $3.69M | $3.71M | $3.74M | $3.79M | — | -0.2% |
| Total assets | $2.29B | $2.00B | $1.30B | $1.15B | $1.09B | — | +14.1% |
| Total current liabilities | $464.89M | $1.13B | $1.07B | $986.48M | $935.00M | — | -58.7% |
| Current debt | $65.43M | $510.56M | $486.53M | $482.28M | $462.35M | — | -87.2% |
| Long-term debt | $384.64M | $386.11M | $385.25M | $331.37M | $330.19M | — | -0.4% |
| Total debt | $450.07M | $896.66M | $871.79M | $813.65M | $792.53M | — | -49.8% |
| Total liabilities | $849.53M | $1.52B | $1.47B | $1.33B | $1.28B | — | -43.9% |
| Retained earnings | -$1.88B | — | — | — | -$2.67B | -$2.66B | — |
| Shareholder equity | $1.44B | $487.97M | -$162.82M | -$174.07M | -$187.57M | — | +194.4% |
| Working capital | $925.52M | -$4.42M | $39.59M | $31.30M | $17.96M | — | +21,025.3% |
| Net tangible assets | $1.43B | $484.28M | -$166.53M | -$177.82M | -$191.36M | — | +195.9% |
| Shares issued | 66.27M | 61.78M | 61.98M | 61.70M | 61.15M | — | +7.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $206.97M | $629.34M | -$33.56M | -$60.99M | -$38.86M | — | -67.1% |
| Depreciation & amortisation | $4.57M | $4.22M | $4.82M | $4.02M | $4.31M | — | +8.3% |
| Stock-based compensation | $29.61M | $30.36M | $29.95M | $30.64M | $30.02M | — | -2.5% |
| Change in working capital | -$7.39M | -$66.82M | $39.86M | $24.64M | -$44.03M | — | +88.9% |
| Operating cash flow | $281.68M | -$7.72M | $73.40M | $2.15M | -$7.34M | — | +3,748.3% |
| Capital expenditure | — | — | -$3.39M | -$53.00K | -$4.34M | -$703.00K | — |
| Investing cash flow | -$2.85M | -$6.75M | -$3.39M | -$53.00K | -$4.34M | — | +57.7% |
| Share buybacks | -$51.55M | -$51.86M | $0 | $0 | $0 | — | +0.6% |
| Financing cash flow | -$46.12M | -$36.83M | $8.52M | $38.85M | $6.98M | — | -25.2% |
| Free cash flow | $270.73M | -$7.72M | $70.01M | $2.10M | -$12.38M | — | +3,606.5% |
| End cash position | $812.26M | $572.82M | $616.04M | $539.09M | $494.05M | — | +41.8% |
Options analytics
Put / call volume
0.31
Call-heavy session
Put / call open interest
0.41
Positioning, not flow
Max pain
170.00
-24.8% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
566
Contracts, this expiry
Put volume
174
Contracts, this expiry
Heaviest call OI
370.00
17 contracts
Heaviest put OI
160.00
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.77 | 0.90 | +17.4% |
| Mar 2026 | -0.08 | 0.27 | +429.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.94 | 3 | $365.23M | +71.0% |
| Next quarter | 1.16 | 3 | $413.11M | +66.9% |
| Current year | 12.79 | 5 | $1.37B | +90.3% |
| Next year | 9.62 | 5 | $2.01B | +46.9% |
Analyst targets & ownership
Mean target$306.74
High target$350.58
Low target$262.75
Implied upside34.53%
Analyst count20
ConsensusSTRONG BUY
Strong buy / Buy5 / 15
Hold0
Sell / Strong sell0 / 0
Held by insiders0.78%
Held by institutions104.07%
Institutions holding444
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
227.46
+0.24% from price
SMA 20
238.17
-5.09% from price
SMA 50
247.63
-8.72% from price
SMA 100
245.73
-7.21% from price
SMA 200
235.76
-4.12% from price
EMA 12
231.26
-1.40% from price
EMA 26
238.69
-4.47% from price
EMA 50
243.67
-6.43% from price
RSI (14)
36.6
Neutral
MACD (12,26,9)
-7.43
Hist -0.70
ATR (14)
7.32
3.24% of price
Realised vol 30D
45.0%
Annualised
Bollinger upper
265.33
20, 2σ
Bollinger lower
211.02
20, 2σ
50 / 200 cross
Golden
247.63 vs 235.76
Trend bias
Below 200
-4.12%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.27
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
45.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-19.5%
Peak to trough
Max drawdown 5Y
-58.8%
Peak to trough
ATR 14
7.32
3.24% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
3.96M
Prior 3.69M
Change vs prior
+7.4%
Shorts adding
% of float
7.13%
Normal
% of shares out
6.02%
Against total outstanding
Days to cover
6.3
Crowded exit
Float
65.64M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 15, 26 | Raymond James | DOWNGRADE | Strong Buy | Outperform |
| Sep 2, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Sep 1, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Sep 1, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 31, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Aug 31, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Aug 31, 26 | Stifel | MAINTAINED | Buy | Buy |
| Aug 31, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 27, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Aug 19, 26 | BMO Capital | INITIATED | — | Outperform |
| Aug 14, 26 | TD Cowen | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-29
Corporate Changes & Voting Matters
6-K · 2026-09-15
Corporate Changes & Voting Matters
6-K · 2026-09-09
Corporate Changes & Voting Matters
6-K · 2026-08-31
Corporate Changes & Voting Matters
6-K · 2026-08-13
Corporate Changes & Voting Matters
6-K · 2026-08-12
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-07-15
Headlines
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
GlobeNewswire · 16h ago
This Biotech’s Proprietary Platform Could Unlock Its Next Growth Phase
Insider Monkey · 2d ago
Ascendis Pharma (ASND) Authorizes $400M Share Buyback
Insider Monkey · 16d ago
Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs
Simply Wall St. · 18d ago
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
Insider Monkey · 19d ago
BioMarin Stops Voxzogo Development for Noonan Syndrome
Zacks · 21d ago
Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says
MT Newswires · 21d ago
Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls
The Fly · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.